TY - GEN
T1 - Electrokinetic transport of molecules through nanochanneled membranes
AU - Grattoni, Alessandro
AU - Liu, Xuewu
AU - Wang, Zongxing
AU - Gill, Jaskaran
AU - Ziemys, Arturas
AU - Ferrari, Mauro
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2010
Y1 - 2010
N2 - Our research group was the first one to microfabricate and demonstrate nano-channels in silicon membranes (1, 2). We employed nano-channeled chips to provide immuno-isolation for cell transplantation towards the treatment of diabetes (3), for biomolecular separation (4), and for the controlled passive and active release of drug molecules from implanted capsules (5). We showed that the constraints placed upon molecular agitation in nano-channels affected their concentration-driven transport kinetics (6, 7). A zero-order passive release of biological molecules was achieved, by the rational tailoring of nano-channels dimensions. This achievement allowed releasing of a constant amount of drugs over a long period of time. However, the development and optimization of many drug therapies require long-term drug delivery with controlled but variable dosage using miniaturized systems (8). Moreover, application such as drug release from implanted devices requires tight operational control, of regulatory agency caliber. We have engaged in the development and characterization of elecroosmotic nano-channels membranes, and present our results in this communication. These include the influence of the drug release rate on nanochannel size, membrane configuration, and applied voltage.
AB - Our research group was the first one to microfabricate and demonstrate nano-channels in silicon membranes (1, 2). We employed nano-channeled chips to provide immuno-isolation for cell transplantation towards the treatment of diabetes (3), for biomolecular separation (4), and for the controlled passive and active release of drug molecules from implanted capsules (5). We showed that the constraints placed upon molecular agitation in nano-channels affected their concentration-driven transport kinetics (6, 7). A zero-order passive release of biological molecules was achieved, by the rational tailoring of nano-channels dimensions. This achievement allowed releasing of a constant amount of drugs over a long period of time. However, the development and optimization of many drug therapies require long-term drug delivery with controlled but variable dosage using miniaturized systems (8). Moreover, application such as drug release from implanted devices requires tight operational control, of regulatory agency caliber. We have engaged in the development and characterization of elecroosmotic nano-channels membranes, and present our results in this communication. These include the influence of the drug release rate on nanochannel size, membrane configuration, and applied voltage.
KW - Drug release
KW - Electroosmosis
KW - Silicon nanochannel
UR - http://www.scopus.com/inward/record.url?scp=77955076803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955076803&partnerID=8YFLogxK
U2 - 10.1115/nemb2010-13236
DO - 10.1115/nemb2010-13236
M3 - Conference contribution
AN - SCOPUS:77955076803
SN - 9780791843925
T3 - Proceedings of the ASME 1st Global Congress on NanoEngineering for Medicine and Biology 2010, NEMB2010
SP - 131
EP - 134
BT - Proceedings of the ASME 1st Global Congress on NanoEngineering for Medicine and Biology 2010, NEMB2010
PB - ASME
T2 - 1st Global Congress on NanoEngineering for Medicine and Biology: Advancing Health Care through NanoEngineering and Computing, NEMB 2010
Y2 - 7 February 2010 through 10 February 2010
ER -